Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
MeSH Number(s)
D12.776.157.530.400.175.125
D12.776.543.550.425.175.125
D12.776.543.585.400.175.125
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Harvard Catalyst Profiles by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 5 | 5 |
| 1994 | 0 | 5 | 5 |
| 1995 | 2 | 2 | 4 |
| 1996 | 5 | 0 | 5 |
| 1997 | 5 | 2 | 7 |
| 1998 | 6 | 1 | 7 |
| 1999 | 6 | 0 | 6 |
| 2000 | 6 | 4 | 10 |
| 2001 | 7 | 3 | 10 |
| 2002 | 7 | 2 | 9 |
| 2003 | 4 | 4 | 8 |
| 2004 | 9 | 5 | 14 |
| 2005 | 5 | 5 | 10 |
| 2006 | 5 | 1 | 6 |
| 2007 | 8 | 3 | 11 |
| 2008 | 5 | 3 | 8 |
| 2009 | 10 | 7 | 17 |
| 2010 | 6 | 7 | 13 |
| 2011 | 8 | 1 | 9 |
| 2012 | 5 | 4 | 9 |
| 2013 | 4 | 2 | 6 |
| 2014 | 6 | 2 | 8 |
| 2015 | 9 | 6 | 15 |
| 2016 | 11 | 5 | 16 |
| 2017 | 10 | 3 | 13 |
| 2018 | 4 | 1 | 5 |
| 2019 | 8 | 7 | 15 |
| 2020 | 7 | 3 | 10 |
| 2021 | 7 | 10 | 17 |
| 2022 | 2 | 9 | 11 |
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Need to study simplification of gastrointestinal medication regimen in cystic fibrosis in the era of highly effective modulators. Pediatr Pulmonol. 2023 03; 58(3):811-818.
-
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. Am J Respir Crit Care Med. 2022 12 01; 206(11):1361-1369.
-
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome. Microbiol Spectr. 2022 10 26; 10(5):e0145422.
-
CFTR variants are associated with chronic bronchitis in smokers. Eur Respir J. 2022 08; 60(2).
-
Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction. Eur Respir J. 2022 07; 60(1).
-
Defining and identifying early-onset lung disease in cystic fibrosis with cumulative clinical characteristics. Pediatr Pulmonol. 2022 10; 57(10):2363-2373.
-
Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis. J Cyst Fibros. 2022 09; 21(5):807-810.
-
Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res. 2022 06; 9(1).
-
DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis-associated variants in the Severe Asthma Research Program. Pediatr Pulmonol. 2022 07; 57(7):1782-1788.
-
A Potent Inhibitor of the Cystic Fibrosis Transmembrane Conductance Regulator Blocks Disease and Morbidity Due to Toxigenic Vibrio cholerae. Toxins (Basel). 2022 03 18; 14(3).